Search

Displaying results 1151 - 1160 of 10000 in total
  1. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11042
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)
  2. Drug

    Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14419
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) hemagglutinin antigen (formaldehyde inactivated)
  3. Drug

    Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14603
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (UV, formaldehyde inactivated)
  4. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14611
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (UV, formaldehyde inactivated)
  5. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14612
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (UV, formaldehyde inactivated)
  6. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal … Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular

    Mixtures: PHESGO® 1200 MG/600 MG, PHESGO® 1200 MG/600 MGProducts: HERCEPTIN (SOLUTION FOR INJECTION 600 MG/5 ML), HERCEPTİN 600 MG/5 ML S.C. ENJEKSİYONLUK ÇÖZELTİ, 1 ADET
  7. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. … [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]

    Products: CIDOFOVIR INJECTION 375 MG/5 ML (75 MG/ML), CIDOFOVIR INJECTION 375 MG/5ML
  8. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.

    Products: TAFINLAR 50 MG KAPSUL, 20 ADET, TAFINLAR (CAPSULES 50 MG)
  9. Drug

    Gadobenic acid

    go.drugbank.com/drugs/DB00743
    ApprovedInvestigational

    [A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166] … [A263086] It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity.

    Mixtures: MULTIHANCE INJECTION 10 ML, MULTIHANCE INJECTION 10 MLCategories: Compounds used in a research, industrial, or household setting
  10. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island

    Products: LIKMUN-E, RAPAMUNE 1 MG 100 FILM DRAJE